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The objective of this paper is to prepare vinpocetine (VIN) inclusion complex and evaluate
its brain targeting effect after intranasal administration. In the present study, VIN inclu-
sion complex was prepared in order to increase its solubility. Stability constant (Kc) was
used for host selection. Factors influencing properties of the inclusion complex was
investigated. Formation of the inclusion complex was identified by solubility study and
DSC analysis. The brain targeting effect of the complex after intranasal administration was
studied in rats. It was demonstrated that properties of the inclusion complex was mainly
influenced by cyclodextrin type, organic acids type, system pH and host/guest molar ratio.
Multiple component complexes can be formed by the addition of citric acid, with solubility
improved for more than 23 times. Furthermore, In vivo study revealed that after intranasal
administration, the absolute bioavailability of vinpocetine inclusion complex was 88%.
Compared with intravenous injection, significant brain targeting effect was achieved after
intranasal delivery, with brain targeting index 1.67. In conclusion, by intranasal adminis-
tration of VIN inclusion complex, a fast onset of action and good brain targeting effect can
be achieved. Intranasal route is a promising approach for the treatment of CNS diseases.
© 2015 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. All
rights reserved.1. Introduction
Along with the acceleration of population aging, how to treat
cerebrovascular diseases effectively is a great challenge.
The blood brain barrier (BBB) represents an insurmountable
obstacle fora largenumberofdrugsand is themajorbottleneck
in drug delivery to the brain [1,2]. So far, lots of attempts have
beenmade to overcome theBBB, including theusage of carrier-henyang Pharmaceutica
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nanoparticles and micelles with different administration
routes [3]. Among them, intranasal drug delivery is one of the
focused delivery options for brain targeting. As a kind of non-
invasive route, intranasal drug delivery has the advantages of
rapid onset of action, good patient compliance, and avoiding
hepatic first pass effect with high bioavailability [4]. Moreover,
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cells of the body, so the olfactory mucosa could be considered
asa ‘windowto thebrain’ [5], thus theBBBcanbepassedbyand
a wide variety of therapeutic agents, including both small
molecules and macromolecules, can be successfully delivered
to the CNS by intranasal route [6].
Vinpocetine (VIN) is a vasoactive vinca alkaloid and a syn-
thetic derivative of apovincamine, it is commonly used in
clinical practice for the treatment of disorders arising from
cerebrovascular and cerebral degenerative diseases [7,8].
However, due to its poor solubility in water [9], short elimina-
tion half-life (1e2 h) and extensive metabolism in liver (~75%)
[10,11], it has low oral bioavailability (6.7%) in human beings
[12] and therefore lowdrug concentration in the brain, limiting
its application in the clinic. Therefore, it is highly desirable to
designappropriatedrugdeliverysystemforVINwith improved
drug solubility and enhanced brain targeting effect.
Different methods can be used to increase the solubility of
poorly soluble drugs. Among them, inclusion complex for-
mation is an effective one. Cyclodextrin (CD) and its de-
rivatives, which can form “inclusion complexes” in aqueous
solutions, have beenwidely used in pharmaceutics to increase
the solubility, stability and bioavailability of poorly soluble
drugs, with reduced irritation and side effects [13].
Thus, the objective of this study is to improve the solubility
of VIN by inclusion complex formation and increase its brain
targeting effect by intranasal administration. Solubility phase
diagram was used to guide the preparation of the inclusion
complex. The complexes formation was confirmed by DSC
and solubility test. Influence of different factors on the prop-
erties of the complex was investigated. Brain targeting effect
of VIN inclusion complex was evaluated after intranasal
administration in rats.2. Materials and methods
2.1. Materials
Vinpocetine (VIN) was purchased from Haide Corporation
(Benxi, Liaoning, China). b-cyclodextrin (b-CD) was from
Tianjin Chemical Reagent Company (Tianjin, China), hydrox-
ypropyl-b-cyclodextrin (HP-b-CD) was from Deli Biological
Chemical Corporation (Xi'an, Shanxi, China), randomly
methyl-b-cyclodextrin (RM-b-CD) was from Xinda Chemical
Corporation (Jinan, Shandong, China), citric acid was from
Zhengxin Institute Department of reagents (Shenyang,
Liaoning, China), tartaric acid was from Bodi Chemical Com-
pany (Tianjin, CA), Methanol (HPLC grade) was supplied by
Yuwang (Jinan, Shandong, China). All other reagents and
buffer components were of analytical grade.
2.2. Solubility test
The solubility of VIN under different conditionswasmeasured
using shake-flask method at 37 C [14]. Briefly, an excess
amount of VIN was added to 5 ml of specific solvents and the
samples were placed in a water bath and stirred at 100 r/min
for 48 h. Thereafter, the resulting suspensions were filtered
through a 0.45 mm membrane filter and concentration of VINin the filtrate was analyzed using high performance liquid
chromatography (HPLC) method after dilution. The HPLC in-
strument consists of Agilent C18 column (4.6 mm*150 mm,
5 mm, USA) and UV detector set at 273 nm. Mobile phase was a
mixture of methanol: ammonium acetate (15.4 g/l) (80:20, v/v),
filtered through 0.45 mm membrane filter, the flow rate was
1.0 ml/min, injection volume 20 ml, oven temperature 35 C.
2.3. Phase solubility studies
The phase solubility study of VIN with b-CD (0e12.5 mM), HP-
b-CD (0e90.0 mM) and RM-b-CD (0e77.0 mM) was performed
at 37 C in distilled water (pH¼ 6.3). The stability constant (Kc)
of the complex was calculated according to the following
equation [15]:
Kc ¼ slope=interceptð1 slopeÞ
The higher the Kc value, the better the stability.
2.4. Preparation of inclusion complex
The inclusion complex was prepared by dissolving followed
freeze-drying method. Briefly, 1400 mg of HP-b-CD was dis-
solved in 10 ml of distilled water at room temperature and a
solution of 10 ml 2% (w/v) citric acid or tartaric acid, aqueous
solution containing appropriate amount of vinpocetine (the
molar ratio of VIN and HP-b-CD was 1:1, 1:2, 1:3) was added
under stirring, ultrasounded for 15 min to dissolve the drug
and HP-b-CD. The resulting solution was stirred at 50Cfor
1e2 h. After equilibrium to room temperature, pH of the so-
lution was adjust to approximately 5 unless specially indi-
cated, and filtered through 0.45 mmmembrane filter, the clear
solution was frozen at 20 C and subsequently freeze-dried
(FD-1 freeze-dryer apparatus, Beijing Medicine and Health
Technology Co, Beijing, China) for 48 h. The inclusion rate is
calculated according to the following equation:
The inclusion rate ¼ weight of VIN in inclusion complex
weight of VIN fed initially
2.5. Characterization of inclusion complexes
Formation of inclusion complexes was identified by solubility
study as described in 2.2 and DSC analysis. The DSC curves
were determined with a DSC instrument (DSC-1, METTLER,
Switzerland) under the following conditions: samples
(2e3 mg) were hermetically sealed in a flat-bottomed
aluminum pan and heated, with an empty pan sealed as
reference, over a temperature range of 20e250 C with the
heating rate of 10 C under nitrogen gas.
2.6. In vivo analytical method of VIN
VIN concentration in plasma was analyzed by HPLC after
solvent extraction [17]. Briefly, 200 ml of the plasma sample
was mixed with 40 mL of internal standard (8 mg/ml proges-
terone) and 50 mL of 0.5 M NaOH solution for 30 s by vortexing
in a glass tube. Then hexane (3 ml) was added for VIN
extraction. The mixture was centrifugalized and the super-
natantwas transferred into another glass tube and the solvent
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residue was redissolved in 100 ml of methanol by vortexing,
followed by centrifugation at 6650 g/min for 10 min. The su-
pernatant was analyzed by HPLC at wavelength 228 nm to
increase the sensitivity; the other analytical conditions were
the same as described in Section 2.2. For the brain homoge-
nate, 0.5 ml of homogenate was mixed with 40 ml of internal
standard and 50 ml of 0.5 MNaOH solution by vortexing for 30 s
in a glass tube, hexane (6 ml) was added for extraction, and
then follow the procedures described above.
The HPLC method described above for VIN assay in the
plasma and in the brain tissuewas specific and efficient. There
was no interference from endogenous components observed
at the retention time of the analytes in the chromatogram.
Good linear relationship between drug concentration and
peak area was established, the concentration range was
20e1000 ng/ml for plasma sample and 20e800 ng/ml for brain
samples. The mean extraction recoveries were 90.18% and
85.39% for plasma and brain samples, respectively. The RSDs
of intra- and inter-day precision were both below 10.0%.
2.7. Pharmacokinetic studies in rats
In vivo absorption of VIN inclusion complex after intravenous
and intranasal administration was studied in rats. All animal
studies were approved by the University Ethics Committee
and were carried out in accordance with the Principle of
Laboratory Animal Care. The Sprague Dawley rats (male,
180e200 g) were supplied by the Lab Animal Center of She-
nyang Pharmaceutical University and randomly divided into
two groups, 15 rats in each group. In group I the complex was
given by intravenous injection via tail vein, in group II the
complex was administrated intranasally according to the
method reported previously [16], both with a single dose of
1 mg/kg. Blood samples (approximately 0.5 ml) were with-
drawn from retro-orbital plexus at 0, 3, 5, 10, 20, 30 min, 1, 2,
3 h post-dosing (n ¼ 3) and centrifuged at 6650 g/min for
10 min. The supernatant plasma samples were stored at
20 C until analysis.
For the biodistribution study, the rats were sacrificed at
10 min, 30 min, 1 h, 2 h after dosing (n ¼ 3) and the brain was
removed after cardiac perfusion with 0.9% NaCl solution, and
drug concentration in the brain was determined by homoge-
nizing the organs in 2-fold ice-cold 0.9% NaCl solution before
analysis.
2.8. Statistical analysis
Pharmacokinetic parameters, the maximum plasma concen-
tration of the drug (Cmax), the time to reach Cmax (Tmax) and
AUC were calculated from the plasma concentrationetime
profiles. The absolute bioavailability (F) of the intranasally
administrated inclusion complex was calculated by
comparing their AUC with that of intravenous injection usingTable 1 e Influence of pH on the solubility of VIN at 37 C (n ¼
pH 2 3 4
Solubility C (mg/ml) 5.43 1.87 0.51DAS 2.1.1 software. Significance of difference was evaluated
using one-way ANOVA at the probability level of 0.05. Drug
targeting index (DTI) was calculated by the following formula,
DTI >1 was considered as brain-targeting distribution [18].
DTI ¼

AUCbrain

AUCplasma

i:n
AUCbrain

AUCplasma

i:v
3. Results and discussion
3.1. Influence of pH on the solubility of VIN
To optimize the condition for inclusion complex preparation,
influence of pH on the solubility of VINwas studied firstly. The
pH range was selected based on the physiological condition of
human body fluid and nasal mucus [19]. Buffer solutions with
pH 2.0, 4.0, 5.0, 6.0, 6.8, 7.4 were used in this study.
As shown in Table 1, with the increase of pH, the solubility
of VIN decreased significantly. The solubility of VIN was
5.43 mg/ml at pH 2, and decreased to 2.44 mg/ml at pH 6.8. As
VIN is a kind of weak basic drug (pKa 7.31), its solubility was
greatly affected by pH, therefore it is absolutely essential to
monitor pH during the experiment.
3.2. Influence of cyclodextrin type on the stability of the
inclusion complex
To screenwhich kind of cyclodextrin can form stable complex
with VIN and explore the complexation ratio, phase solubility
diagrams of VIN with three types of cyclodextrin, including
b-CD, and two water soluble cyclodextrin derivatives, 2-
hydroxypropyl derivatives of b-cyclodextrin (HP-b-CD) and
randomly methyl-b-cyclodextrin (RM-b-CD) were studied in
distilled water (pH 6.3). As shown in Fig. 1, irrespective of
cyclodextrin type, a typical AL type diagramwas observed and
the solubility of VIN increased almost linearly with the in-
crease of CD concentration, implying that soluble VIN and CD
inclusion complexes were formed at molar ratio 1:1.
Meanwhile, the apparent stability constant (KC) of different
complexes, which represents strength of the interaction and
stability of the complex, were calculated, it was in the order:
HP-b-CD (77.77 M1) > RM-b-CD (74.76 M1) > b-CD (66.92 M1).
No significant difference in bonding force between VIN and
HP-b-CD, RM-b-CD were found, both are higher than b-CD
based complex. Considering the fact that HP-b-CD has better
safety profile for intranasal administration than that of RM-
b-CD [20], and the poor aqueous solubility of b-CD (1.85% at
25 C), HP-b-CD was selected for further investigation.
However, even when the concentration of HP-b-CD was as
high as 15%, the solubility of VINwas just 50e60 mg/ml, far less
than the dose required for intranasal delivery. It is reported
that multicomponent complexation technology is quite
effective in increasing drug concentration in the cavity of3).
5 6 6.8 7.4
0.093 0.012 2.44*103 7.8*104
Fig. 1 e Phase solubility diagrams of VIN with different kinds of b-CD in distilled water (pH¼ 6.3) and 37 C (A:b-CD, B: HP-b-
CD, C: RM-b-CD).
Table 2 e Factors influencing properties of VIN inclusion
complex.
Factors The concentration
of VIN(mg/ml)
Inclusion
rate (%)
Organic acid Citric acid 4743.75 85.39
Tartaric acid 4054.45 72.98
Molar ratio
(VIN:CD)
1:1 4875.93 29.26
1:2 4854.07 58.25
1:3 4743.75 85.39
Temperature
(C)
40 4594.04 82.69
50 4743.75 85.39
60 4666.84 84.00
Time (h) 1 4730.73 85.15
2 4743.75 85.39
3 4437.64 79.88
System pH 4.5 5491.14 98.80
5 4743.75 85.39
5.5 363.31 6.54
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tight fit between the complexed molecule and the CD must
occur (Kc at least 103 M1) [21], apparently, the interaction
between VIN and cyclodextrin was far below this value.
Fortunately, it was found that citric acid (CA) can increase the
solubility of VIN significantly [22], and the solubility
enhancement of CA overweighed the influence of solution pH.
For example, the solubility of VIN in 2% CA was 15 mg/ml (the
pH of different concentrated CA solution was typically in the
range of pH 3e4), and in comparison, its solubility in pH 3.0
medium was only 1.87 mg/ml, implying free water soluble
complexes were formed between VIN and CA [22]. Therefore,
adding CA might be an effective way to improve VIN con-
centration in the HP-b-CD by forming multicomponent com-
plex. It has been reported that simultaneous complexation
with these acids significantly increased the solubilizing
power, reducing the amount of cyclodextrin necessary for
making the targeted formulation [21].
3.3. Factors influencing properties of VIN inclusion
complex
To optimize properties of VIN inclusion complex, influence of
VIN and HP-b-CD molar ratio (1:1, 1:2, 1:3), organic acids type
(citric acid and tartaric acid), inclusion complex preparationtemperature (40, 50, 60 C), inclusion incubation time (1, 2, 3 h),
and the system pH (4.5, 5, 5.5) on achieved drug concentration
and the inclusion rate were investigated. The results are
presented in Table 2.
First of all, by keeping solution pH at 5, influence of
different parameters was investigated. Taking both drug
a s i a n j o u r n a l o f p h a rma c e u t i c a l s c i e n c e s 1 0 ( 2 0 1 5 ) 1 1 4e1 2 0118concentration and inclusion rate into consideration, citric acid
was more effective than that of tartaric acid and was selected
for the followed study. No significant difference in drug con-
centration was found (P > 0.05) when the molar ratio of VIN
and HP-b-CD was 1:1, 1:2, 1:3, but the inclusion rate increased
with the increase of molar ratio, so VIN and HP-b-CD molar
ratio 1:3 was selected. Influence of temperature on properties
of the inclusion complex was not significant in the range of
40e60 C, 50 C was selected. When the incubation time was
1 h or 2 h, there was no significant difference in drug con-
centration or inclusion rate, however, when the reaction time
was prolonged to 3 h, the drug concentration decreased
slightly, therefore reaction time 1e2 h was selected. As to the
influence of system pH, drug concentration decreased
approximately 14% when the pH was changed from 4.5 to 5,
however, a sharp decrease in drug concentration was found
when the pH was adjusted to 5.5, probably the organic acid
was neutralized by the added base and destroyed the multi-
clathrate complex [21]. Since pH 4.5e6.5 is commonly
accepted for intranasal administration [23], pH 4.5 was
selected for the followed study.
Therefore, the final complex was prepared by using the
following conditions: VIN andHP-b-CDmolar ratio 1:3, organic
acid types: citric acid, inclusion temperature 50 C, incubation
time 1e2 h, the system pH 4.5.
3.4. Identification of inclusion complex formation
Formation of inclusion complexes was identified by both DSC
and solubility study. The DSC profiles of the pure drug, the
ternary system of the multicomponent complex and physical
mixture are shown in Fig. 2. The thermal curve of pure VIN
was typical of a crystalline anhydrous substance with a sharp
endothermic peak at 151.98 C corresponding to its melting
point [24]. The melting peak was also observed in the physical
mixture. Concerning the ternary system of the multicompo-
nent complex, the thermal characteristic peak of VIN was
shifted to a lower temperature at around 148.0 C and itsFig. 2 e DSC curves of VIN, VIN/HP-b-CD/CA inclusion complex
inclusion complex,C: physical mixture).intensity decreased significantly, indicating that most of drug
substance existed in amorphous state and/or being included
in the complex [24]. These results suggest that VIN/HP-b-CD/
CA inclusion complexes were formed.
Inclusion complex formation was further confirmed by
solubility test. The drug solubility of the inclusion complex
lyophilized powder was 4.74 mg/ml (pH ¼ 4.5), and it was
0.2 mg/ml for the free drug measured at exactly the same
condition. This study indicated that the solubility of VIN in the
inclusion complex was about 23-fold higher than that of the
free drug in water.
3.5. Pharmacokinetic and biodistribution studies
The concentrationetime profiles of VIN in the plasma and in
the brain after i.v and intranasal administration of VIN in-
clusion complex in rats are shown in Fig. 3. The pharmaco-
kinetic parameters are summarized in Table 3. The plasma
AUC value of VIN after intranasal administration was slightly
lower than that after i.v. administration, and the absolute
bioavailability was 88%, with Tmax 10 min, implying that VIN
can be quickly absorbed into systemic circulation comparable
with that of intravenous injection.
As for brain targeting, shorter Tmax and higher drug con-
centration in the brain was found after intranasal adminis-
tration of VIN complex. The mean Cmax values in the brain
(153.5 ng/g) after i.n administrationwere found to bemarkedly
higher than those obtained after i.v administration (78.5 ng/g).
The peak concentration in the brain occurred at 10 min after
i.n administration, and it was faster than that of i.v (30 min)
route. Moreover, the brain AUC0e180 min value was signifi-
cantly higher after intranasal administration compared to i.v.
administration, with DTI value 1.67, indicating significant
brain-targeting effect was achieved. This is quite reasonable
and can be explained by the fact that part of the drug could
reach the brain directly via olfactory mucosa in the nose
whereas after i.v administration, the drug will be firstly
absorbed into systemic circulation then redistributed in theand their physical mixture (A: VIN, B: VIN/HP-b-CD/CA
Table 3 e The pharmacokinetic parameters in plasma
and brain after intravenous (i.v) and intranasal (i.n)
administration of VIN inclusion complex in rats (n ¼ 3).
Parameters i.v i.n
(AUC0et)plasma(ng$min/ml) 22,391.0 ± 1169.7 19,700.4 ± 1288.4
*
(AUC0et)brain(ng$min/g) 9229 ± 1615.0 13,544 ± 1012.0
**
(Cmax)plasma (ng/ml) 459.4 ± 14.7 301.0 ± 9.1
**
(Cmax)brain(ng/g) 78.5 ± 11.5 153.5 ± 16.2
**
(Tmax) plasma(min) 2 ± 0 10 ± 0
**
(Tmax)brain(min) 30 ± 11.54 10 ± 0
**
*P < 0.05, compared to the i.v administration.
**P < 0.01, compared to the i.v administration.
Fig. 3 e Concentrationetime profiles of VIN in the plasma
and in the brain after intranasal and intravenous injection
in rats (n ¼ 3) (A: plasma, B: brain).
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drug concentration in plasma than that in brain after i.v.
injection.4. Conclusions
In the present study, VIN inclusion complex was prepared in
order to increase its solubility. Factors influencing properties
of the inclusion complex was investigated. Formation of the
inclusion complex was identified by solubility study and DSC
analysis. In vivo study in rats revealed that after intranasal
administration of vinpocetine inclusion complex, the absolute
bioavailability was 88%. Significant brain targeting effect was
found with intranasal administration of VIN compared with
that of intravenous injection, with brain targeting index 1.67.
In conclusion, by intranasal administration of VIN inclusion
complex, a fast onset of action and good brain targeting effect
can be achieved.r e f e r e n c e s
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